1 Immunity to non-dengue flaviviruses impacts dengue virus IgG ELISA specificity in Cambodia 2 Camila Odio¹, Christina Yek^{2, 3*}, Chloe M. Hasund^{1*}, Somnang Man², Piseth Ly², Sreynik 3 4 Nhek², Sophana Chea², Chanthap Lon², Charlie Voirin¹, Rekol Huy⁴, Rithea Leang⁴, Chea Huch⁴, L. Fabiano Oliveira^{2, 3}, Jessica E. Manning^{2, 3,+}, Leah C. Katzelnick^{1,+} 5 6 **Affiliations:** ¹Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, 7 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 8 9 MD 20892, USA, ²International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Phnom Penh, Cambodia, ³Laboratory of 10 Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National 11 Institutes of Health, Bethesda, MD 20892, ⁴National Center for Parasitology, Entomology, and 12 Malaria Control, Ministry of Health, Phnom Penh, Cambodia. 13 14 *Authors made equal contributions to this manuscript. 15 16 17 *Corresponding authors: 18 19 Leah Katzelnick PhD MPH 20 Chief, Viral Epidemiology and Immunity Unit National Institutes of Allergy and Infectious Diseases, National Institutes of Health 21

22

23

Building 33, Room 3W10A, 33 North Drive

Bethesda, MD 20892-3203

Phone: 240-627-3276, Email: <u>leah.katzelnick@nih.gov</u>
Jessica Manning MD MSc
Director, International Center of Excellence in Research CAMBODIA
National Institutes of Allergy and Infectious Diseases, National Institutes of Health
Email: jess.manning@gmail.com

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Abstract 92 words Seroprevalence studies are the gold standard for disease surveillance, and serology was used to determine eligibility for the first licensed dengue vaccine. However, expanding flavivirus endemicity, co-circulation, and vaccination complicate serology results. Among 713 healthy Cambodian children, a commonly used indirect dengue virus IgG ELISA (PanBio) had a lower specificity than previously reported (94% vs. 100%). Of those with false positive PanBio results, 46% had detectable neutralizing antibodies against other flaviviruses, with the highest frequency against West Nile virus (WNV). Immunity to non-dengue flaviviruses can impact dengue surveillance and potentially pre-vaccine screening efforts. Manuscript: 1,696 words **Background** The genus Orthoflavivirus includes multiple pathogenic mosquito-borne viruses including dengue viruses 1-4 (DENV1-4), Japanese encephalitis virus (JEV), West Nile virus (WNV), Zika virus (ZIKV) and yellow fever virus (YFV) [1]. With expanding vector habitats, known flaviviruses are rising in global incidence, and novel flaviviruses are emerging [2, 3]. These flaviviruses commonly co-circulate, and the antibodies induced by one exposure may cross-react with others in the genus [4]. Additionally, affected areas use vaccines to protect against JEV and YFV, further complicating serology. As flaviviruses expand their range and vaccination increases, differentiating true exposure from cross-reactivity is not only difficult, but also increasingly important to guide diagnostic, preventative, and therapeutic measures.

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Accurately characterizing population level immunity to DENV is important for current dengue vaccination efforts. Dengvaxia (Sanofi Pasteur), the first widely approved dengue vaccine, was originally recommended in 2016 by the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) panel for use in areas with ≥70% DENV seroprevalence in children age 9 and older, with seroprevalence most often measured using common IgG ELISAs [5]. When it was later shown that Dengvaxia increases the risk of severe disease in DENV-naïve individuals, the WHO recommended use of highly specific individual-level testing of DENV immunity to confirm vaccine eligibility, as well as use in high-risk populations in endemic areas [6][7]. The World Health Organization has since recommended that the second licensed dengue vaccine QDENGA (Takeda) be introduced to children aged 6 to 16 years, also in highly endemic areas [8]. Given the lack of observed vaccine-induced protection against DENV3 in seronegative individuals and the unknown protection against DENV4 [9], a strategy based on population-level estimates of endemicity has the potential to increase disease risk for seronegative individuals. Population-level serosurveys for DENV conducted for surveillance purposes generally use commercial IgG ELISAs. The plaque reduction neutralization test (PRNT), which measures neutralizing antibodies (nAbs) to DENV, is considered the gold standard for evaluating specificity but requires intensive and specialized labor. The PanBio indirect DENV IgG ELISA (Abbott, Brisbane, QLD, Australia) is one of the most commonly used assays for measuring DENV immunity, and the manufacturer reports 100% specificity based on 108 DENV-naïve individuals from endemic areas [10]. Separate work demonstrated 99% specificity of this ELISA using DENV1-4 PRNT₅₀≥10 as the standard for DENV immunity in a cohort of 534 individuals from both the USA and dengue-endemic regions before 2016 [11]. However, the PanBio indirect

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

DENV IgG ELISA yields higher false positivity rates when evaluated with individuals positive to other flaviviruses, including those who had received an inactivated JEV vaccine (3%), or had immunity against ZIKV (34%) or WNV (51%) [11]. The degree to which immunity to other flaviviruses affects DENV serosurveys is dependent on the site, and a major challenge is that the extent of circulation of other flaviviruses is often unknown. For instance, an observational study of children aged 9-14 years in the Philippines in 2017 used a PRNT₇₀≥40 as the indicator of DENV immunity and reported a relatively low ELISA specificity, of 93.4%. Of the false positive samples, 64% had nAb against ZIKV or JEV, in a region where ZIKV was not thought to be widespread. Thus, although the PanBio ELISA has a reportedly high specificity, this number may vary with flavivirus cross-reactivity and expanding co-circulation or vaccination. Here, we examine the performance of the PanBio ELISA in young children in Cambodia, a highly dengue-endemic area. ZIKV was recently found to co-circulate in the area, and JEV is endemic. JEV vaccination campaigns with a live-attenuated JEV vaccine SA14-14-2 started around 2014, and WNV nAb have been identified in birds but not humans [12-15]. Methods The study protocol was approved by the institutional review boards at the US National Institutes of Health and the National Ethics Committee on Human Research in Cambodia. The guardians of all pediatric participants provided signed informed consent to participate in the study. Between July and August of 2018, 771 children aged 2-9 years living in Kampong Speu, Cambodia were enrolled in a prospective longitudinal cohort (NCT03534245) [16]. At entry, the

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

PanBio indirect DENV IgG ELISA was performed on sera from 770 individuals. For the 273 participants with ELISA values >1.1 (defined as DENV positive by the manufacturer), PRNTs were performed using clinical isolates of DENV1-4 [17]. All PRNTs were performed on Vero cells, as described previously, starting at a serum dilution of 1:5 followed by the addition of an equal volume of virus. Thus, the lower limit of detection was a dilution of 1:10 [18]. The nAb titer was defined as the reciprocal of the calculated dilution wherein virus infectivity was reduced by 50% (PRNT₅₀). PRNT₅₀≥1:10 (reported as PRNT₅₀≥10) against any DENV serotype was considered immune to that serotype. To assess for non-dengue flavivirus nAbs, PRNTs were performed using the following strains: ZIKV-PARAIBA/2015, a chimeric vaccine candidate, WNV/DEN4Δ30 [19], and JEV vaccine strain SA14-14-2 (Figure 1A-B). Consistent with prior classifications, seropositivity to any non-dengue flavivirus was defined as PRNT₅₀≥10 [20-22]. Statistical comparisons were done in RStudio for macOS (2022.07.1, Build 554) using tidyverse and gtsummary packages. Heatmaps were generated in PRISM (v.9 for macOS). **Results** Of the 770 individuals, n=440 had ELISA<0.2 and were considered DENV naïve per work confirming a strong correlation between ELISA<0.2 and negative PRNT [23]. Fifty-seven individuals were excluded: 44 had ELISA values between 0.2-0.9 without a confirmatory PRNT and 13 had ELISA values between 0.9-1.1, which the manufacturer considers equivocal immunity. Of the 273 individuals with ELISA>1.1, n=28 were DENV negative by PRNT ('false positive'), n=245 were DENV positive ('immune'), and there were no false negatives, resulting in a 100% sensitivity and 94% specificity of the ELISA assay. Comparison of the naïve, false positive, and immune groups revealed that both the mean age and ELISA value of the false

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

positive group fell between those of the naïve and immune groups (p<0.001, Table 1A). Over the two years of surveillance, there were few PCR-confirmed cases of symptomatic dengue (n=46) with no differences in frequency among groups (p=0.7). We hypothesized that the discordance between the DENV ELISA IgG and PRNT results could be due to cross-reactivity against non-dengue flaviviruses. To test this, we compared the frequencies of nAbs against JEV, ZIKV, and WNV in the false positive individuals versus n=50 randomly chosen naïve individuals (Figure 1A-B). Consistent with prior classifications, seropositivity was defined as PRNT₅₀≥10 [20-22]. Overall, 46% of the false positive group had PRNT₅₀ \geq 10 against \geq 1 other flavivirus versus 20% of the naive group (p=0.020, Table 1B). Although the false positive group had higher percentages of individuals with positive JEV and ZIKV nAbs, only WNV nAbs were significantly more common than in the naïve group (0% vs. 25%, p<0.001). To further assess these trends, we tested n=21 individuals with DENV ELISA>1.1 and DENV PRNT between 10-20 (Figure 1). This group has low DENV nAbs and has been considered DENV negative in other work [16, 23]. When compared to the false positive group, the low DENV nAb group had similar frequencies of JEV, ZIKV, and WNV nAb (p≥0.4 for all three nAbs, Table 1B). Thus, immunity to other flaviviruses may contribute to high ELISA values in individuals with undetectable and low DENV nAbs. To help identify the primary exposure in the 13 individuals with PRNT₅₀ \geq 10 against \geq 2 flaviviruses, PRNT₉₀ titers were calculated [4]. Of these, n=4 had PRNT₉₀<10 against all 4 flaviviruses, and n=3 had PRNT₉₀≥10 to multiple flaviviruses: n=2 to JEV and WNV, n=1 to JEV, WNV, and ZIKV (Figure 1C-D). Six individuals had PRNT₉₀≥10 against only 1 flavivirus:

n=1 to ZIKV, n=3 to JEV, and n=2 to WNV. Of the two individuals with PRNT₉₀ \geq 10 against WNV only, one had received a JEV vaccine and had a PRNT₅₀≥10 against JEV and one had PRNT₅₀≥10 against ZIKV. While the PRNT₉₀≥10 against WNV only suggests a primary WNV infection, it is possible that JEV vaccination and ZIKV primary exposure induced highly crossreactive WNV nAb [24]. There were also two individuals with low DENV nAb and PRNT₅₀≥10 against WNV only. Although these individuals did not have PRNT₉₀≥10 against DENV or WNV, one had WNV titer that was 2-fold higher than DENV titer. Again, this finding is suggestive of primary WNV infection, but cross-reactivity after DENV exposure cannot be ruled out. Regardless of the WNV nAb source, this immunity was common and likely central to the decreased ELISA specificity observed.

Discussion

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

We found that the PanBio DENV indirect IgG ELISA has a lower specificity than reported in prior studies. This discrepancy may be partially explained by the assay's detection of WNV nAb with potential contributions by ZIKV and JEV nAb. Notably, JEV vaccination can induce WNV cross-reactivity [25], and it is possible that the WNV nAb were induced by JEV vaccination or infection. Alternatively, the WNV nAbs may represent true WNV exposure, underlining the need for ongoing vigilance for WNV circulation in humans in Cambodia. Additionally, half of the false positive results remained unexplained, potentially due to waning immunity or infection by unidentified flaviviruses.

Clinicians, investigators, and public health authorities should be aware that expanding flavivirus co-circulation and vaccination could increasingly impact serology results. Serosurveys conducted

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

for vaccination campaigns to identify populations where dengue is endemic may overestimate dengue burden as a result of false positivity due to infection or vaccination with other flaviviruses. Such population-based strategies are of particular concern when identifying target populations for dengue vaccines where safety in DENV seronegative individuals has not yet been confirmed. Adverse events in these individuals could greatly impact vaccine trust and uptake, as occurred with Dengvaxia [26]. For vaccines that are known to be unsafe in seronegative individuals like Dengvaxia, pre-vaccination screening is required to determine vaccine eligibility, which allows individuals to make informed decisions about their own vaccine risk and benefit. It is recommended that past infection be confirmed either by virological assay or by two specific serological assays, such as the anti-DENV1-4 NS1 ELISA IgG and a IgG rapid test [7]. Evaluation of false positivity due to infection with other emerging flaviviruses is critical to ensuring the safety of this screening approach. Overall, our study demonstrates that the PanBio IgG ELISA and even PRNT results should be interpreted with caution in areas with flavivirus co-circulation and vaccines, and multiple tests may be required to confirm DENV seroprevalence.




Figure 1. Neutralizing antibody titers against DENV, JEV, WNV, ZIKV in individuals who were false positive (ELISA>1.1, DENV PRNT₅₀<10), naïve (ELISA<0.2), or had low DENV nAb (ELISA>1.1, DENV PRNT₅₀ of 10-20) as measured by PRNT₅₀ (A-B) and PRNT₉₀ titers (C-D). PRNT₉₀ titers were only measured in those with nAb against ≥2 non-dengue flaviviruses.

Table 1. Characteristics and immune profiles of individuals who were naïve (ELISA<0.2), false positive (ELISA>1.1, PRNT₅₀<10), or DENV immune (ELISA>1.1, PRNT₅₀≥10). The presence of neutralizing antibodies against non-dengue flaviviruses were compared in the naïve and false positive groups and between the false positive and the low DENV immune group (ELISA>1.1, PRNT₅₀ 10-20).

A. Cohort characteristics

Characteristics	Naïve	False positive	Immune (n=245)	p-value [†]
	(n=440)*	(n=28)		
Age	4.9 (2.0)	6.0 (2.2)	6.8 (2.2)	< 0.001
Sex				0.2
Female	230 (52)	10 (36)	126 (51)	
Male	210 (48)	18 (64)	119 (49)	
ELISA IgG value	0.03 (0.04)	2.00 (0.72)	2.92 (0.84)	< 0.001
Dengue case				0.7
No dengue	321 (91)	22 (92)	156 (93)	
Symptomatic	32 (9)	2 (8)	12 (7)	
dengue				
Unknown [‡]	87	4	77	

B. Immunity subset analysis

Immunity	Naïve	p-value§	False positive	p-value [¶]	Low DENV nAb
profile	(n=50)		(n=28)		(n=21)
JEV nAb		0.058		0.4	

Negative	41 (82)		17 (61)		16 (76)
Positive	9 (18)		11 (39)		5 (24)
ZIKV nAb		0.3		0.4	
Negative	48 (96)		25 (89)		17 (81)
Positive	2 (4)		3 (11)		4 (19)
WNV nAb		<0.001		0.5	
Negative	50 (100)		21 (75)		14 (67)
Positive	0 (0)		7 (25)		7 (33)
≥1 Flavivirus	10 (20)	0.020	13 (46)	>0.9	10 (48)
positive					
≥2 Flavivirus	1 (2)	0.003	7 (25)	>0.9	5 (24)
positive					

210 *Mean (SD) or no. (%)

209

217

- [†]One-way ANOVA, Pearson's Chi-squared test; Fisher's exact test
- [‡]Unknown indicates that participant was lost to follow-up prior to final study visit at 24 months
- 213 §Fisher's exact test comparing naïve vs. false positive group.
- Fisher's exact test comparing false positive group vs. low DENV nAb group.
- Dengue virus, DENV; Japanese encephalitis virus, JEV; neutralizing antibodies, nAb; West Nile
- virus, WNV; Zika virus, ZIKV

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

Acknowledgements: The authors would like to thank Patrick Mpingabo for his support establishing ELISA assays to evaluate samples for antibodies against the nonstructural-1 proteins of JEV, ZIKV, and WNV. These assays were not ultimately used in the manuscript. We would also like to thank Kelsey Lowman for her support completing the WNV and JEV PRNT assays. Funding: This research was supported by the Intramural Research Program at the National Institute of Allergy and Infectious Diseases. **Conflict of Interest:** The authors declare no conflict of interest. This work was presented as a poster at the American Society of Tropical Medicine and Hygeine annual conference in October 2023. References 1. Postler TS, Beer M, Blitvich BJ, et al. Renaming of the genus Flavivirus to Orthoflavivirus and extension of binomial species names within the family Flaviviridae. Archives of Virology **2023**; 168:224. 2. Du M, Jing W, Liu M, Liu J. The Global Trends and Regional Differences in Incidence of Dengue Infection from 1990 to 2019: An Analysis from the Global Burden of Disease Study 2019. Infectious Diseases and Therapy **2021**; 10:1625-43. 3. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nature Microbiology 2020; 5:796-812.

- 4. Chan KR, Ismail AA, Thergarajan G, et al. Serological cross-reactivity among common
- flaviviruses. Front Cell Infect Microbiol **2022**; 12:975398.
- 5. Secretariat SWGoDVaWHO. Background paper on dengue vaccines. Available at:
- 244 https://terrance.who.int/mediacentre/data/sage/SAGE Docs Ppt Apr2016/10 session dengue/A
- pr2016 session10 dengue vaccines.pdf. Accessed 11/17/2023.
- 6. WHO. Dengue vaccine: WHO position paper. Weekly epidemiological record **2018**; 93:457-
- 247 76.
- 7. Prevention CfDCa. Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue
- Vaccine. Available at: https://www.cdc.gov/dengue/vaccine/hcp/testing.html. Accessed October
- 250 31 2023.
- 8. Takeda. Takeda's Dengue Vaccine Recommended by World Health Organization Advisory
- 252 Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to
- 253 16 Years. Available at: https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Dengue-
- 254 Vaccine-Recommended-by-World-Health-Organization-Advisory-Group-for-Introduction-in-
- 255 <u>High-Dengue-Burden-and-Transmission-Areas-in-Children-Ages-Six-to-16-Years/</u>. Accessed
- 256 October 31 2023.
- 9. Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year Efficacy and Safety of Takeda's Dengue
- Vaccine Candidate (TAK-003). Clinical Infectious Diseases **2021**.
- 259 10. Abbott. Panbio™ DENGUE IgG CAPTURE ELISA. Available at:
- 260 https://www.globalpointofcare.abbott/au/en/product-details/panbio-dengue-igg-capture-
- elisa.html. Accessed August 29 2023.

- 262 11. Bonaparte M, Zheng L, Garg S, et al. Evaluation of rapid diagnostic tests and conventional
- 263 enzyme-linked immunosorbent assays to determine prior dengue infection. J Travel Med 2019;
- 264 26.
- 12. Yek C, Li Y, Pacheco AR, et al. National dengue surveillance, Cambodia 2002-2020. Bull
- 266 World Health Organ **2023**; 101:605-16.
- 13. Duong V, Ong S, Leang R, et al. Low Circulation of Zika Virus, Cambodia, 2007-2016.
- 268 Emerg Infect Dis **2017**; 23:296-9.
- 269 14. Horwood PF, Duong V, Laurent D, et al. Aetiology of acute meningoencephalitis in
- 270 Cambodian children, 2010-2013. Emerg Microbes Infect 2017; 6:e35.
- 271 15. Auerswald H, Ruget AS, Ladreyt H, et al. Serological Evidence for Japanese Encephalitis
- and West Nile Virus Infections in Domestic Birds in Cambodia. Front Vet Sci 2020; 7:15.
- 273 16. Manning JE, Chea S, Parker DM, et al. Development of Inapparent Dengue Associated With
- 274 Increased Antibody Levels to Aedes aegypti Salivary Proteins: A Longitudinal Dengue Cohort in
- 275 Cambodia. The Journal of Infectious Diseases 2021.
- 276 17. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live
- dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
- 278 Am J Trop Med Hyg **2001**; 65:405-13.
- 279 18. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and
- validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to
- four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med
- 282 Hyg **2013**; 88:962-70.

- 19. Pierce KK, Whitehead SS, Kirkpatrick BD, et al. A Live Attenuated Chimeric West Nile
- Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older
- Adult Volunteers. The Journal of Infectious Diseases **2016**; 215:52-5.
- 20. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol **2010**;
- 287 17:1055-65.
- 21. Sornjai W, Jaratsittisin J, Auewarakul P, Wikan N, Smith DR. Analysis of Zika virus
- neutralizing antibodies in normal healthy Thais. Sci Rep **2018**; 8:17193.
- 290 22. Kaiser JA, Barrett ADT. Twenty Years of Progress Toward West Nile Virus Vaccine
- 291 Development. Viruses **2019**; 11.
- 292 23. Lopez AL, Adams C, Ylade M, et al. Determining dengue virus serostatus by indirect IgG
- 293 ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a
- prospective population-based study. The Lancet Global Health **2021**; 9:e44-e51.
- 24. Hou B, Chen H, Gao N, An J. Cross-Reactive Immunity among Five Medically Important
- 296 Mosquito-Borne Flaviviruses Related to Human Diseases. Viruses 2022; 14:1213.
- 25. Mansfield KL, Horton DL, Johnson N, et al. Flavivirus-induced antibody cross-reactivity. J
- 298 Gen Virol **2011**; 92:2821-9.

- 299 26. Larson HJ, Hartigan-Go K, de Figueiredo A. Vaccine confidence plummets in the
- 300 Philippines following dengue vaccine scare: why it matters to pandemic preparedness. Hum
- 301 Vaccin Immunother **2019**; 15:625-7.